Refining endpoints in brain tumor clinical trials

Journal of Neuro-Oncology

Volumn 108, Issue 2, 2012, Pages 227-230

  Meyers, Christina A ^a   Rock, Edwin P ^b   Fine, Howard A ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Brain cancer; Clinical trials; Neurocognitive Function

Indexed keywords

BEVACIZUMAB;

ARTICLE; BRAIN RADIOGRAPHY; BRAIN TUMOR; CANCER PROGNOSIS; CANCER THERAPY; CLINICAL TRIAL (TOPIC); COGNITION; GLIOBLASTOMA; HUMAN; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; TREATMENT OUTCOME; TREATMENT RESPONSE;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; COGNITIVE THERAPY; ENDPOINT DETERMINATION; HUMANS; QUALITY OF LIFE; RESEARCH DESIGN;

EID: 84864046044     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0813-8     Document Type: Article

References (15)

1. Meyers CA, Hess KR, Yung WKA, Levin VA (2000) Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18:646-650 (Pubitemid 30078546)
2. Meyers CA, Hess KR (2003) Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol 5:89-95 (Pubitemid 36416837)
3. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28: 1943-1972
4. O'Shaughnessy JA, Wittes RE, Burke G et al (1991) Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J Clin Oncol 9: 2225-2232
5. Brown PD, Jensen AW, Felton SJ et al (2006) Detrimental effects of tumor progression on cognitive function of patients with highgrade glioma. J Clin Oncol 24:5427-5433 (Pubitemid 46623176)
6. Wefel JS, Cloughsey TF, Zazzali JL et al (2011) Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13:660-668
7. Meyers CA, Brown PD (2006) The role and relevance of neurocognitive assessment in clinical trials of patients with central nervous system tumors. J Clin Oncol 24:1305-1309 (Pubitemid 46622034)
8. Meyers CA, Wefel JS (2003) The use of the Mini Mental State Examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol 21:3557-3558 (Pubitemid 46594045)
9. Meyers CA, Smith JA, Bezjak A et al (2004) Neurocognitive function and progression in patients with brain metastases treated with whole brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22:157-165 (Pubitemid 41095128)
10. Wolfson AH, Bae K, Komaki R et al (2011) Primary analysis of a phase II randomized trial radiation therapy oncology group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys 81:77-84
11. Correa DD, Maron L, Harder H et al (2007) Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 18:1145-1151 (Pubitemid 47244358)
12. Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12:703-708
13. Benedict RHB, Schretlen D, Groninger L, Brandt J (1998) Hopkins Verbal Learning Test-Revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 12:43-55 (Pubitemid 28168220)
14. Benton AL, KdeS Hamsher (1989) Multilingual aphasia examination. AJA Associates, Iowa City
15. Lezak MD, Howieson DB, Loring DW (2004) Neuropsychological assessment. Oxford University Press, New York